Microalbuminuria is the earliest clinical evidence of diabetic nephropathy, but the mechanisms linking hyperglycemia and kidney complications are not clear. The aim of this study was to evaluate whether enhanced oxidative stress in patients with microalbuminuria can contribute to diabetic nephropathy development through downregulation ofthe antiapoptotic gene Bcl-2 that promotes in turn a pro-inflammatory status. We studied 30 patients with type 1 diabetes (15 with and 15 without microalbuminuria) compared to 15 matched healthy controls. Plasma oxidant status, and expression of Bcl-2, activated NF-kB, inducible Nitric Oxide synthase (iNOS), and monocyte chemoattractant protein (MCP)-1 in circulating monocytes were evaluated at baseline and after 8-week oral vitamin E treatment (600 mg b.i.d.), Bcl-2 expression was significantly reduced in microalbuminuric diabetic patients as a consequence of increased oxidant burden secondary to persistent hyperglycemia. Bcl-2 down-regulation was associated with enhanced expression ofNF-kB, iNOS and MCP-l, and showed a strong correlation with the albumin excretion rate. Low Bcl-2 expression and high inflammatory status were normalized by vitamin E both in vivo and in vitro. Our study showed that Bcl-2 down-regulation in diabetic patients with poor glycemic control results in the activation of the NF-kB pathway leading to the development of nephropathy. Vitamin E might provide a novel form of therapy for prevention of nephropathy in diabetic patients in which an acceptable glycemic control is difficult to achieve despite insulin therapy.
Microalbuminuria is the earliest clinical evidence of diabetic nephropathy, but the mechanisms linking hyperglycemia and kidney complications are not clear. The aim of this study was to evaluate whether enhanced oxidative stress in patients with microalbuminuria can contribute to diabetic nephropathy development through downregulation ofthe antiapoptotic gene Bcl-2 that promotes in turn a pro-inflammatory status. We studied 30 patients with type 1 diabetes (15 with and 15 without microalbuminuria) compared to 15 matched healthy controls. Plasma oxidant status, and expression of Bcl-2, activated NF-kB, inducible Nitric Oxide synthase (iNOS), and monocyte chemoattractant protein (MCP)-1 in circulating monocytes were evaluated at baseline and after 8-week oral vitamin E treatment (600 mg b.i.d.), Bcl-2 expression was significantly reduced in microalbuminuric diabetic patients as a consequence of increased oxidant burden secondary to persistent hyperglycemia. Bcl-2 down-regulation was associated with enhanced expression ofNF-kB, iNOS and MCP-l, and showed a strong correlation with the albumin excretion rate. Low Bcl-2 expression and high inflammatory status were normalized by vitamin E both in vivo and in vitro. Our study showed that Bcl-2 down-regulation in diabetic patients with poor glycemic control results in the activation of the NF-kB pathway leading to the development of nephropathy. Vitamin E might provide a novel form of therapy for prevention of nephropathy in diabetic patients in which an acceptable glycemic control is difficult to achieve despite insulin therapy.
The proportion of patients with end-stage renal disease (ESRD) caused by diabetes has progressively increased during the last few decades, and diabetic nephropathy is now the most common cause of ESRD in the western world. In patients with type I diabetes, the development of kidney complications, known as diabetic nephropathy, consists of several stages: the onset of microalbuminuria, its progression to overt proteinuria, and progression of proteinuria to endstage renal disease (l) . Retrospective studies in type I diabetic patients reported a risk of progression from microalbuminuria to overt proteinuria of about 80% over the subsequent 6-14 years (2) . Since then, there has been broad acceptance of albumin excretion rate (AER) >20 ug/min as the earliest clinical sign of incipient diabetic nephropathy (3) . Prospective studies have addressed the relative importance of various risk factors on the development of microalbuminuria. A causal relationship between chronic hyperglycemia and diabetic microvascular disease, long inferred from a variety of animal and clinical studies, has now been definitely established by data from the Diabetes Control and Complications Trial (4) , which clearly demonstrated that the onset of microalbuminuria is determined by the level of glycemic control and can be delayed by intensive diabetes treatment. However, the pathophysiological pathway(s) by which hyperglycemia may contribute to the development of nephropathy in diabetes are not clearly understood. Among the sequelae of hyperglycemia, excess oxidative stress has captured considerable attention as a potential mechanism of late diabetic complication (5) . In particular, hyperglycemia-induced oxidative stress has been proposed as a major cause of diabetic nephropathy (6) . Animal models implicate that oxidative stress accompanying the early onset of diabetes increases the kidney's susceptibility to develop diabetic nephropathy (7) . Moreover, in a recent study (8) , a 4-week treatment with vitamin E plus vitamin C in patients with type 2 diabetes with micro/macroalbuminuria significantly lowered albumin excretion rate by 19%, thus' suggesting a potential protective effect on the kidneys in diabetic patients.
One possible mechanism for this detrimental effect of oxidative stress on renal function is the influence on the activation status of the transcription factor NF-kB (9) . NF-kB is a heterodimer comprised of p50 and p65 (ReI A) subunits, and is found sequestered in the cytoplasm of unstimulated cells as an inactive complex with the NF-kB inhibitory protein IkB (10) . Phosphorylation of IkB and translocation of activated NF-kB into the nucleus results in gene expression of NF-kB controlled target genes such as leukocyte adhesion molecules, cytokines and inducible nitric oxide synthase (iNOS) (10) . Interestingly, recent studies showed that NF-kB is activated by poor glycemic control in ex vivo isolated peripheral blood mononuclear cells (PBMCs) of patients with type 1 diabetes mellitus, and that NF-kB activity correlated with the degree of diabetic nephropathy, as reflected by albuminuria (11) . However, the complete mechanism of NF-kB regulation by hyperglycemia in the setting of type 1 diabetes remains unknown.
Bc1-2 is a cell-death regulator whose function is modulated by complex homo-and heterodimerizations with its pro-apoptotic homologous Bax (12) . More recently, it has been demonstrated that the function of Bc1-2 is not limited to its anti-apoptotic potential, but is involved in a complex regulatory network that serves to down-regulate cell activation by the dose-dependent inhibition of the transcription factor NF-kB (13) and ofNF-kB-controlled genes (14) . Thus, these findings support a correlation between the antiapoptotic activity of Bc1-2 and its anti-inflammatory effect, exerted through inhibition ofNF-KB and NF-KB-dependent pro inflammatory genes. We speculated that oxidative stress induced by insufficient glycemic control in patients with type 1 diabetes could influence the expression of Bcl-2 in circulating inflammatory cells, and that this effect could contribute to inflammatory mediator biosynthesis and progressive decline in glomerular function. Therefore, in this study, we investigated whether higher levels of glycosyated hemoglobin and lipid peroxidation are associated with reduced Bcl-2 expression in patients with type 1 diabetes, and whether Bcl-2 levels correlate with NF-kB activation, inflammatory mediator production and AER. Furthermore, additional studies have been performed both in vivo and in vitro to assess the influence of hyperglycemia per se and antioxidant supplementation on Bcl-2 gene expression.
MATERIALS AND METHODS

Patients
The study was carried out in 30 young, type 1 diabetic patients (aged 18±5 yr) admitted to the Pediatric Division of our University and divided into two groups according to present persistent microalbuminuria: 15 patients with microalbuminuria (group A) and 15 patients without microalbuminuria (group B). Recruitment was complete when two predetermined equal groups of 15 patients according to evidence of present persistent microalbuminuria were achieved. Persistent microalbuminuria was defined as AER between 20 and 200 ug/min in 2 out of 3 overnight urine collections performed over six months. In addition, 15 healthy volunteers without evidence of disease were studied as control group (group C). The 3 groups were matched for age, sex, body mass index (BMI), blood pressure and serum lipids (Table I) . Diabetic groups were also carefully matched for duration of the disease and insulin requirement, and were not taking any other drug or antioxidant supplement except insulin. None of the diabetic patients was affected by other diabetic complications such as retinopathy (evaluated by stereoscopic fundus photography) or neuropathy (evaluated by nervous conduction velocity and autonomic tests). The study was approved by local ethics review committees. Informed consent was obtained from all patients.
Biochemical measurements
Blood and urine samples were collected from each subject after fasting and plasma HbAlc, serum total protein and urinary albumin concentration were measured as previously reported (15) . All the patients were tested four times a year for HbA1c and the mean value was used for statistical analysis.
Evaluation ofoxidant status
Fluorescent products of lipid peroxidation (FPLPs), an index of plasma lipid peroxide content, were estimated spectrofluorometrically as previously described (16) . Thiobarbituric acid reactive substances (TBARS), an index of lipid peroxidation in native LDL (n-LDL), were measured fluorometrically as previously described. (17) . Freshly diluted tetramethoxypropane, which yields malondialdehyde (MDA), was used as a standard, and results were expressed as nanomoles ofMDA equivalents per milligram of LDL-C (nmol MDNmg LDL-C). Finally, the plasma content ofthe endogenous antioxidant vitamin E was determined by high-performance liquid chromatography as previously described (16) .
Blood Cells isolation
PBMCs were isolated from whole blood as previously described (18) . Cellular yield was determined by using a hemocytometer (Sigma, Saint Louis, Missouri); cell viability,assessedby Trypan blue dye exclusion,was >95%.
RT-PCR
Total RNA was isolated by using Tri-Reagent according to the manufacturer's protocol (Sigma). Aliquots of 5 mg of total RNA were reverse-transcripted into cDNA and polymerase chain reaction (PCR) for Bel-2 was performed as described by Karakas et al (19) . Primer sequences for Bcl-2 were: 5'-CCGCTACCGCCGCGACTTC (sense) and 5'-AAACAGAGGCCGCATGCTG (antisense) (19) .
Quantitative RT-PCR
A competitive template serving as internal standard for quantification of Bcl-2 mRNA was designed and constructed as described by Becker-Andre et al (20) .
Western blot analysis
After protein extraction from PBMCs, Western blot was performed as previously described (21) (22) by using anti-human Bcl-2 and anti-human BAX (Dako, Carpinteria, CA), anti-human iNOS and anti-human MCP-l (R&D Systems Inc., Minneapolis, MN), antihuman p65/Re1A antibodies (Roche Biochemicals, Manheim, Germany). Protein bands were analysed using densitometric analysis (AlphaEase 5.02) and expressed as arbitrary densitometric units (DD).
Effect of Vitamin E on analysed gene expression in vivo
High-dose vitamin E pills (600 mg twice a day, during meals, for two months) were administrated to group A patients. Blood samples were collected from each patient before and after vitamin E supplementation. Systemic oxidant status and expression of the studied genes were determined in terms of RNA and protein expression as described above.
Effect of Vitamin E on Bcl-2 expression in vitro
PBMCs (4xl 0 6 ) isolated from blood samples of the 15 diabetic patients with microalburninuria were cultured in the presence or absence of25 IlM vitamin E for 24 h. The dose and time incubation of vitamin E were chosen on the basis of previous pilot studies. Expression of Bcl-2, p65/RelA, MCP-l and iNOS was determined as described above.
Effect ofhyperglycemia on Bcl-2 expression
PBMCs (4x10 6 ) from 5 healthy blood donors were cultured during normo-(5 mM glucose) and hyperglycemic (25 mM glucose) conditions. Mannitol (25 mM) was used as osmolar control. In addition, PBMCs were incubated with different doses of vitamin E (6, 12, 25 or 50 IlM) during hyperglycemic conditions. After 24 hours of incubation, Bcl-2, p65/RelA, MCP-l and iNOS expression was determined as previously described.
Statistical analysis
For clinical data, variables were compared by use ofthe x 2 test. Differences in biochemical variables between groups were analyzed by Student's unpaired t test and by ANOVA. The correlation between biochemical parameters was assessed by linear regression analysis. Statistical significance was indicated by p<0.05. All calculations were performed using the computer program SPSS 10.05
RESULTS
Glycemic control and renal function
Fasting glucose level (10.2±2 vs 7.7±2 rnmol/L, mean±SD) and mean HbAlc (9.6±1% vs 7.3±1%, mean±SD) were significantly higher (P=O.009) in micro albuminuric diabetic patients as compared to normoalbuminuric subjects (Table I) .
Accordingly to the Diabetes Control and Complications Trial (4), persistent hyperglycemia resulted to be a crucial determinant of early renal dysfunction. In fact, HbAlc showed a significant positive correlation with AER (R2=O.75, P<O.OOOI) in patients with microalbuminuria. 
Reduced Bcl-2 expression in diabetic patients with microalbuminuria
Mononuclear cells from diabetic patients with microalbuminuria (complicated diabetes) showed significantly (P<O.OOO I) lower Bcl-2 protein expression as compared to both normoalbuminuric diabetic patients (non complicated diabetes) (2595±106 vs 6322±322 DU) and healthy subjects (2595±106 vs 3810±212 DU) ( Fig. 2a ). Thus, Bcl-2 activity in diabetic patients with renal dysfunction was reduced by~32% as compared to healthy subjects. In contrast, there were no significant differences in the expression of Bax protein in all groups of patients ( Fig. 2a ). Finally, we observed a marked reduction also in the levels of Bcl-2 mRNA in the diabetic patients with microalbuminuria ( Fig.  2b) . Thus, these data suggest a down-regulation of Bcl-2 at the transcriptional level in inflammatory cells of diabetic patients with microalbuminuria and poor glycemic control.
Enhanced NF-kB activity in diabetic patients with microalbuminuria
In order to identify the activated form of p65 (p65a), we performed Western blot analysis by using a specific antibody that selectively recognizes an epitope overlapping the nuclear location signal [NLS] of the p65 subunit and therefore selectively stains the unbound activated form ofNF-kB (25) (26) . In inflammatory cells of patients with microalbuminuria, activated NF-kB was significantly (P <O.OOI) higher (6423±389 DU) with respect to both diabetic patients without microalbuminuria (2 11 4± I07 DU) and healthy controls (l634±182 DU) ( Fig. 3a) . When FPLPs , TBARS and vitamin E were determined in the same samples , the increase in NF-kB activation responded to the increase in lipid peroxidation . Furthermore, the densitometric values of activated NF-kB showed a direct correlation with poor glycemic control as reflected by HbA Ic (R2=0.792, P<O.OO 1), and an inverse assoc iation with the densitometric values for BcI-2 protein (R2=-0.688, P<O.OO I) .
Enhanced expression of inflammatory genes in diabetic patients with microalbuminuria.
Monocyte expression of MCP-1 and iNOS, two NF-kB-dependent inflammatory genes, was significantly (P<O.OO 1) increased in microalbuminuric diabetic patients (7228±381 and 6929±148 DU, respectively) with respect to both diabetic patients without microalbuminuria (3848±221 and 3484±189 DU) and healthy controls (2716±141 and 2321±161 DU) (Fig. 3b ). When regression analysis was performed with the use of densitometric values, both genes showed a positive association with NF-kB activity (R2=O.728,
Fig. 4. (A) Correlation between mean HbAlc and Bcl-2 expression. Bcl-2 expression in PBMCs isolated from diabetic patients with poor glycaemic control was assessed by Western blot and quantified by densitometric analysis. Bcl-2 expression showed a statistically significant inverse association with HbA1c. Each dot representse one patient. Results shown are the mean value ofthree experiments. (B)
Reduced systemic Bcl-2 expression as consequence of persistent hyperglicemia. Bcl-2 expression was measured during normo-and hyperglicemic conditions in PBMCs isolated from healthy volunteers. Bcl-2 expression was strongly reduced in monocytes exposed to 25 mM glucose in cells treated with 5 mM glucose. In contrast, no changes were observed during incubation with mannitol 25 mM. P<O.OOl, and R2=O.699, P<O.OOI, respectively) and an inverse correlation with Bcl-2 (R2=-O.748, P<O.OOl, and R2=-O.682, P<O.OOI , respectively).
Reduced Bc/-2 expression associated with early renal dysfunction.
To assess whether reduction of the antiinflammatory activity of Bcl-2 in circulating mononuclear cells may contribute to the progression of renal complications in type 1 diabetic patients, we analyzed the correlation between Bcl-2 expression group of diabetic patients with poor glycemic control and microalbuminuria. HbAlc showed a significant inverse association with Bcl-2 protein (R2=-0.581 , P<O.OOl, Figure 4a ) and mRNA (R2=-0.628, P<O.OOl) values as quantified by densitometry.
In the second in vitro study, we investigated Bcl-2 expression in normo-and hyperglycemic conditions in PBMCs isolated from healthy blood donors. Expression of Bcl-2 protein (Fig. 4b ) and mRNA (data not shown) was strongly reduced in monocytes exposed to 25 mM glucose with respect to cells treated with 5 mM glucose. In contrast, no changes were observed during incubation with mannitol.
Bcl (as quantified by densitometric analysis) andAER in the 15 diabetic patients with signs of diabetic nephropathy. Using this approach, Bcl-2 expression showed a strong inverse association with AER (R 2=_ 0.803, P<O.OOOl).
d.) vitamin E. In vivo vitamin E therapy significantly raised Bcl-2 expression to levels observed in healthy subjects. (B) Effect ofin vitro vitamin Eon Bcl-2 expression in PBMCs isolatedfrom the 5 diabetic patients with microalbuminuria and lowest Bcl-2 expression at baseline. Incubation of monocytes with vitamin E was able to normalize Bcl-2 expression to levels observed in healthy subjects. (C) Effect ofin vitro vitamin E on BcJ-2 expression in healthy monocytes
Reduced Bel-2 expression as a consequence of persistent hyperglycemia
In the first study, we analyzed the correlation between mean HbAlc and Bcl-2 expression in the
Effect of vitamin E supplementation on oxidant status and Bel-2 expression
In the first in vivo study, we assessed the level of systemic oxidative stress and Bcl-2 expression in the subset of diabetic patients with microalbuminuria before and after an 8-week treatment with high doses of vitamin E. Vitamin E supplementation was able to raise vitamin E to the level observed in non complicated diabetic patients and healthy subjects (from 2l±3 to 36±6IlmollL, P<O.OOOl). In addition, both FPLPs and TBARS were significantly (P<O.OOl) reduced after antioxidant treatment (from 22±3 to 16±3 URF/mL, and from O.9±O.09 to O.6±O.08 nmol MDAlmg LDL-C, respectively). At the same time, Bcl-2 protein expression showed a significant increase after vitamin E treatment (Fig.  5a) to a healthy control level. Interestingly, intensity of Bcl-2 expression, as quantified by densitometry, showed a positive correlation with plasma vitamin E before (R2=O.622, P<O .OOl) as well as after treatment (R2=O.7Il, P<O.OOl).
In the second in vitro study, we assessed the effect of vitamin E on Bcl-2 expression in PBMCs isolated from the 5 diabetic patients with microalbuminuria and lowest Bcl-2 expression at baseline. Vitamin E (25 11M) was able to normalize Bcl-2 expression (Fig.  5b) . In contrast, we did not observe any change when cells were incubated with insulin.
Finally, in the last in vitro study we assessed the influence of vitamin E on Bcl-2 expression in monocytes from healthy controls during hyperglycemic conditions (Fig. 5c ). Bcl-2 expression was strongly down-regulated in monocytes exposed to 25 mM glucose, while it was unchanged in monocytes incubated with 25 mM glucose + 25 !!M vitamin E. 
d.) therapy. In vivo vitamin E significantly raised Bel-2 mRNA, thus confirming that normalization ofBel-2 protein expression after vitamin E treatment was due to a direct effect of vitamin E on Bel-2 mRNA biosynthesis
Mechanism by which vitamin E may restore Bel-
expression
In the first study, we evaluated Bcl-2 mRNA expression by quantitative RT-PCR before and after 8week vitamin E supplementation in microalbuminuric diabetic patients and we observed a nearly 80% increase in the amount of mRNA after antioxidant treatment (Fig. 6 ).
In the second in vitro study, we assessed Bcl-2 mRNA expression in PBMCs exposed to 25 mM glucose + 25 !!M vitamin E, with respect to cells treated with 25 mM glucose alone. Bcl-2 mRNA was significantly reduced in cells exposed to hyperglycemic conditions, while co-incubation with vitamin E preserved Bcl-2 loss caused by hyperglycemia. Thus, both these results suggest that vitamin E exerts its protective effect on Bcl-2 expression at the transcriptional level. -65 kDa and quantified by densitometry, they were inversely correlated (R 2=-0.818 , P<O.OO I) . Interestingly, reduction in NF-kB activity in vivo as achie ved by vitamin E resulted in a comparable diminution in the systemic inflammatory status, as reflected by MCP-I and iNOS monocyte gene expression ( Fig. 7) Finally, vitamin E treatment was also associated with improved renal function, as reflected by 31% reduction in AER after 8-week vitamin E therapy (84±34 vs 58±22 ug/rnin, P<0.03).
MCP-1
DISCUSSION
Diabetic nephropathy is the single most common cause of end-stage renal disease in the western world. The development of diabetic nephropathy consists of several stages: the onset of microalbuminuria, its progression to overt proteinuria, and progression of proteinuria to end-stage renal disease (I). Thus, there is broad acceptance of persistent microalbuminuria In diabetic patients with microalbuminuria, vitamin E treatment reduced NF-kB activity to that observed in healthy controls ( Fig. 7) and in normoalbuminuric diabetic patients (data not shown) . Similar results were also found in vitro when freshly isolated PBMCs from the same patients were incubated with 25 !!M vitamin E. Furthermore, when Bcl-2 and p65a were measured in the same samples >20 ug/min as the earliest clinical sign of incipient diabetic nephropathy (3) . Several studies have demonstrated that the duration of diabetes and quality of glycemic control are important predictors for the prevalence of microvascular complications in diabetic patients. However, the precise mechanism(s) by which hyperglycemia may induce microvascular complications in diabetic patients is still unclear.
In this study, we tested the hypothesis that monocyte Bcl-2 expression is downregulated in type I diabetic patients with poor glycemic control by increased oxidant stress induced by persistent hyperglycemia, and this effect could in tum contribute to NF-kB activation, inflammatory mediator biosynthesis, and progressive decline in glomerular function.
We found several important findings in this study. First, we demonstrated that in patients with type 1 diabetes and microalbuminuria, Bcl-2 expression in circulating inflammatory cells is significantly reduced as compared to both non microalbuminuric diabetic patients and healthy subjects. One could argue that this is merely a secondary effect of diabetic disease, however, this hypothesis is unlikely, because patients were well matched for age, sex, duration of disease and insulin requirement. Furthermore, these data are not a result of concomitant therapy, because none of the patients was taking any other medication besides insulin. Second, the low Bcl-2 levels appeared to be a direct effect of poor glycemic control on Bcl-2 expression. This hypothesis is supported by the significant inverse association between HbAlc and Bcl-2 both at the protein and mRNA level. Moreover, it is also confirmed by in vitro experiments, where PBMCs from healthy subjects were incubated in a high and normoglucose environment. In these experiments, Bcl-2 gene expression was strongly reduced at the transcriptional level during hyperglycemic conditions. Third, our study showed that hyperglycemia downregulates Bcl-2 via enhanced oxidant stress. In fact, we observed increased FPLPs and TBARS, and reduced vitamin E levels in diabetic patients with microalbuminuria and poor glycemic control. Notably, changes in oxidant status were associated with high HbAlc and low Bcl-2 values when statistical correlations were performed. Furthermore, the role of oxidative stress in the control ofBcl-2 expression was also confirmed by the ability ofthe antioxidant vitamin E to normalize Bcl-2 level both in vivo and in vitro when added to inflammatory cells during hyperglycemic conditions. Finally, these results are in agreement with the many others showing that hyperglycemia can enhance oxidative stress (5) (6) , and with our previous report showing that amelioration of glycemic control may reduce the level of lipid peroxidation in vivo (26) .
Hyperglycemia-dependent Bcl-2 suppression has direct implications on the activation status of circulating inflammatory cells. In fact, the level of activated NF-kB was significantly higher in diabetic patients with microalbuminuria, showed a significant inverse correlation with Bcl-2, and was normalized similarly to Bcl-2 as consequence of vitamin E supplementation both in vivo and in vitro. NF-kB activation results in the expression of several proinflammatory genes such as iNOS and MCP-I, all potentially involved in the inflammatory reaction leading to mesangial cell proliferation, fibroblast activation, increased extracellular matrix deposition and glomerulosclerosis in patients with diabetes. Although Bcl-2 is only one of several mediators that are altered in diabetes mellitus and lead to nephrovascular complications, we believe that our study provides important information, because it is the first study to demonstrate that Bcl-2 is down-regulated in vivo in patients with type-l diabetes, thus proposing a novel mechanism of NF-kB activation in inflammatory cells, possibly contributing to the rapid progression of early renal damage.
Normalization ofBcl-2 expression and reduction of inflammatory status after 8-week vitamin E treatment is unlikely to be merely an epiphenomenon of insulin therapy, because diabetic groups were carefully matched with respect to insulin requirement. Moreover, insulin failed to restore normal Bcl-2levels and reduce inflammatory status when added to diabetic inflammatory cells in vitro. Again, we might speculate that most of the changes observed in diabetic patients after 8 weeks of vitamin E are simply observed in response to improvement of glycemic control. However, this hypothesis is unlikely, because the active role of vitamin E on Bcl-2 generation is confirmed by the observation that generation of Bel-2 from monocytes in vitro was exclusively upregulated by vitamin E, while changes in osmolar conditions failed to produce any effect. Moreover, glycemic control (as reflected by mean HbAlc) did not change in these patients during the study, thus confirming that normalization in Bcl-2, NF-kB, MCP-l and iNOS gene expression after antioxidant treatment was due to the direct effect of vitamin E and not to improved glycemic control.
Our demonstration of enhanced inflammatory status as a consequence of reduced Bcl-2 expression in diabetic patients with poor glycemic control and early renal dysfunction, is in agreement with the growing body of scientific evidence suggesting that mononuclear inflammatory cells playa key role in the progression of renal damage in diabetes. In fact, monocyte infiltration in the mesangium is associated with fibroblast activation, increased extracellular matrix deposition and trasfonning growth factor (TGF)-13 biosynthesis in diabetic rats, and diffuses glomerulosclerosis in patients with diabetic nephropathy (28).
The critical involvement of the oxidant-sensitive Bcl-2 in the control of the inflammatory pathways leading to diabetic nephropathy is suggested in our study by the strong inverse association between Bcl-2 expression and AER, and by the significant reduction (-31%) in AER after 8 weeks of high-dose vitamin E treatment. Although this study did not have the necessary sample size to test any clinical end-point, it is in agreement with the recent study from Gaede et al (8) , showing that a short-term treatment with vitamin E plus vitamin C may significantly reduce AER in patients with type 2 diabetes.
In conclusion, our study supports the hypothesis that down-regulation of Bcl-2 gene expression in type 1diabetic patients with poor glycemic control results in the activation of the NF-kB pathway leading to recruitment of monocytes and tissue macrophages to the kidney, possibly contributing to the development of diabetic nephropathy. Moreover, these results suggest that the causative role of persistent hyperglycemia in diabetic nephropathy is mediated, at least in part, by increased oxidative stress, and that low plasma levels of vitamin E are important for the development of nephropathy. These fmdings are potentially important from a fundamental standpoint, because they indicate a protective role for Bcl-2 in the evolution of diabetic microvascular complications. From a practical standpoint, these fmdings increase the possibility that vitamin E treatment provides a novel form of complementary therapy in the prevention of microvascular complications in type 1 diabetic patients in whom an acceptable glycemic control is difficult to achieve despite appropriate insulin therapy.
